My guess is the enrolments are finished and results are being...

First 115 Last

Share
Profile

Follow
wop

2,290 Posts.

354

05/03/17

23:08

Post #: 23113925
Share

Originally posted by vwboy ↑

You would think that the three biggest hospitals in the USA are testing the app because it will be a product that they want to use for themselves, not just doing a favour to Resapp to see if it works.

"There are approximately 13.6 million US emergency room visits every year that result in a diagnosis of respiratory disease. 4.6 million of these visits are for children. In the US, 125 million ambulatory care visits are caused by respiratory disease, and ResApp estimates that globally this number is over 700 million.

Used as a clinical aid during emergency room or general clinic consultations, ResApp’s instant, low cost and accurate diagnostic test offers many benefits over the traditional diagnostic pathway. For pneumonia in particular, ResApp’s test costs significantly less than an x-ray and follow-up consultation, and provides accurate results faster which enables physicians to initiate appropriate therapy immediately."

So imo it will be a steady stream of income as soon as FDA approval is given from hospitals and Telehealth providers worldwide.

Cannot see any need for contracts as they would limit usage to a product that will be used all over the world....only other scenario would be a big fat takeover imo.

Expand

My guess is the enrolments are finished and results are being collated now. 1100 enrolments is nothing for 3 massive hospitals of this size. Its not Joondalup. The trails started 9th of December.

I think the results will catch a lot by surprise.

All IMO of coarse.

RAP Price at posting: 32.5¢ Sentiment: Buy Disclosure: Held
14 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce's R327 found effective against E.coli during clinical trial

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom